GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $1.53 billion. The enterprise value is $1.79 billion.
| Market Cap | 1.53B |
| Enterprise Value | 1.79B |
Important Dates
The next confirmed earnings date is Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 347.45 million shares outstanding. The number of shares has decreased by -4.46% in one year.
| Current Share Class | 98.58M |
| Shares Outstanding | 347.45M |
| Shares Change (YoY) | -4.46% |
| Shares Change (QoQ) | -5.93% |
| Owned by Insiders (%) | 3.55% |
| Owned by Institutions (%) | 20.12% |
| Float | 86.43M |
Valuation Ratios
The trailing PE ratio is 49.22 and the forward PE ratio is 27.61. GoodRx Holdings's PEG ratio is 1.66.
| PE Ratio | 49.22 |
| Forward PE | 27.61 |
| PS Ratio | 2.07 |
| Forward PS | 1.86 |
| PB Ratio | 2.38 |
| P/TBV Ratio | 87.37 |
| P/FCF Ratio | 8.05 |
| P/OCF Ratio | 8.00 |
| PEG Ratio | 1.66 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.31, with an EV/FCF ratio of 9.45.
| EV / Earnings | 51.78 |
| EV / Sales | 2.24 |
| EV / EBITDA | 13.31 |
| EV / EBIT | 15.78 |
| EV / FCF | 9.45 |
Financial Position
The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.85.
| Current Ratio | 4.21 |
| Quick Ratio | 3.99 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | 3.84 |
| Debt / FCF | 2.89 |
| Interest Coverage | 2.52 |
Financial Efficiency
Return on equity (ROE) is 5.27% and return on invested capital (ROIC) is 5.53%.
| Return on Equity (ROE) | 5.27% |
| Return on Assets (ROA) | 5.08% |
| Return on Invested Capital (ROIC) | 5.53% |
| Return on Capital Employed (ROCE) | 9.56% |
| Revenue Per Employee | $1.08M |
| Profits Per Employee | $46,883 |
| Employee Count | 738 |
| Asset Turnover | 0.57 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $21.17 million in taxes.
| Income Tax | 21.17M |
| Effective Tax Rate | 37.96% |
Stock Price Statistics
The stock price has decreased by -37.73% in the last 52 weeks. The beta is 1.23, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -37.73% |
| 50-Day Moving Average | 4.23 |
| 200-Day Moving Average | 4.48 |
| Relative Strength Index (RSI) | 51.92 |
| Average Volume (20 Days) | 3,864,962 |
Short Selling Information
The latest short interest is 5.59 million, so 1.61% of the outstanding shares have been sold short.
| Short Interest | 5.59M |
| Short Previous Month | 6.68M |
| Short % of Shares Out | 1.61% |
| Short % of Float | 6.47% |
| Short Ratio (days to cover) | 0.97 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $799.87 million and earned $34.60 million in profits. Earnings per share was $0.09.
| Revenue | 799.87M |
| Gross Profit | 749.28M |
| Operating Income | 113.54M |
| Pretax Income | 55.77M |
| Net Income | 34.60M |
| EBITDA | 134.61M |
| EBIT | 113.54M |
| Earnings Per Share (EPS) | $0.09 |
Balance Sheet
The company has $281.32 million in cash and $547.54 million in debt, giving a net cash position of -$266.22 million or -$0.77 per share.
| Cash & Cash Equivalents | 281.32M |
| Total Debt | 547.54M |
| Net Cash | -266.22M |
| Net Cash Per Share | -$0.77 |
| Equity (Book Value) | 643.03M |
| Book Value Per Share | 1.84 |
| Working Capital | 419.71M |
Cash Flow
In the last 12 months, operating cash flow was $190.60 million and capital expenditures -$1.10 million, giving a free cash flow of $189.50 million.
| Operating Cash Flow | 190.60M |
| Capital Expenditures | -1.10M |
| Free Cash Flow | 189.50M |
| FCF Per Share | $0.55 |
Margins
Gross margin is 93.68%, with operating and profit margins of 14.19% and 4.33%.
| Gross Margin | 93.68% |
| Operating Margin | 14.19% |
| Pretax Margin | 6.97% |
| Profit Margin | 4.33% |
| EBITDA Margin | 16.83% |
| EBIT Margin | 14.19% |
| FCF Margin | 23.69% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.46% |
| Shareholder Yield | 4.46% |
| Earnings Yield | 2.27% |
| FCF Yield | 12.42% |
Analyst Forecast
The average price target for GoodRx Holdings is $5.75, which is 30.98% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.75 |
| Price Target Difference | 30.98% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 5.93% |
| EPS Growth Forecast (5Y) | 89.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 1.65 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 7 |